Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina V in connection with the acquisition of Sushi Yama
Mandate

Vinge advises Litorina V in connection with the acquisition of Sushi Yama

August 11, 2020 Employment and Benefits Banking and Finance Commercial Agreements Intellectual Property M&A Environmental Law Real Estate and Construction

Sushi Yama is a leading sushi restaurant chain with over 45 restaurants in Sweden.

Sushi Yama was the first chain in the Nordics to certify all its restaurants to serve ASC and MSC certified products to its customers. Thanks to the partnership, Sushi Yama can now accelerate its expansion in Sweden and internationally.

Vinge’s team consisted of Jonas Johansson together with, among others, Carl Sander, Christina Odengran and Ellinor Wargenbrant (M&A), Karolina Cohrs and Frida Ställborn (Real estate), Cornelia Medrek and Olof Löfvenberg (Environment), Victoria Ribbnäs and Axel Jansson (Banking and Finance), Ebba Svenburg (Employment), Agnes Perbo and Lova Unge (Commercial Agreements), Ilze Lukins (IP), Johan Wahlbom (Competition law) and VDR-specialist Viktoria Owetz Leyva.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026